Nasoxyl (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasoxyl, is an imidazoline nasal decongestant presented as a nasal spray for topical nasal administration. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children. It is intended for short‑term relief and is available over the counter in the European market.

GNH USA supplies Nasoxyl as a licensed, GDP‑compliant international pharmaceutical product, adhering to EU quality standards and regulatory requirements. The company provides the nasal spray to hospitals, pharmacies and clinics worldwide, supporting reliable access to essential decongestant therapy.

Xylometazoline Hydrochloride is an imidazoline decongestant that reduces nasal airway obstruction in several upper‑respiratory conditions. - Common cold: reduces swelling of nasal mucosa, decreasing blockage and facilitating normal airflow. - Sinusitis: alleviates sinus‑related nasal congestion, helping to relieve pressure and improve sinus drainage. - Allergic rhinitis: diminishes allergic‑induced nasal swelling, providing temporary relief from sneezing and a blocked nose. - Upper respiratory tract infection: eases nasal obstruction associated with viral infections, supporting comfortable breathing. - Air travel‑related congestion: helps restore nasal patency after changes in cabin pressure, reducing discomfort.

Xylometazoline Hydrochloride may cause local or systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation: mild discomfort at the application site. - Sneezing: transient increase in sneezing episodes after dosing. - Dryness of nasal mucosa: reduced moisture leading to a dry feeling. - Headache: mild headache reported by some users. - Unpleasant taste: brief metallic or bitter taste after spray.

Serious or Rare Side Effects: - Rebound congestion (rhinitis medicamentosa) with prolonged use: worsening nasal blockage after stopping the spray. - Elevated blood pressure in susceptible individuals: possible increase in systemic arterial pressure. - Allergic reaction such as rash, itching, or swelling: signs of hypersensitivity requiring medical attention. - Nasal septum perforation (very rare): tissue damage leading to a hole in the septum.

When using Nasoxyl, certain precautions should be observed to ensure safe and effective treatment. - Duration of use: limit to no more than 3‑5 consecutive days to avoid rebound congestion. - Age restrictions: not recommended for children under 2 years unless advised by a healthcare professional. - Pre‑existing conditions: avoid if you have severe hypertension, coronary artery disease, or hyperthyroidism without medical guidance. - Concurrent nasal medications: do not combine with other topical decongestants or vasoconstrictors. - Pregnancy and lactation: use only if clearly needed and prescribed, as safety data are limited. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Xylometazoline Hydrochloride may interact with certain systemic or topical agents, affecting its safety profile.

Major Interactions (Avoid): - MAO inhibitors: may precipitate hypertensive crisis due to additive adrenergic activity. - Other nasal decongestants (e.g., oxymetazoline): combined vasoconstriction can cause severe rebound congestion. - Sympathomimetic oral agents (e.g., pseudoephedrine): additive cardiovascular stimulation may raise blood pressure. - Tricyclic antidepressants: increased sympathetic effects may lead to tachycardia.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs (ACE inhibitors, ARBs, diuretics): monitor blood pressure as nasal vasoconstriction may counteract therapy. - Beta‑blockers: possible reduction in effectiveness due to increased sympathetic tone. - Herbal stimulants (e.g., ephedra): may enhance systemic adrenergic effects, requiring observation. - High caffeine intake: could modestly increase cardiovascular response when combined.